AU2017352033A1 - Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications - Google Patents

Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications Download PDF

Info

Publication number
AU2017352033A1
AU2017352033A1 AU2017352033A AU2017352033A AU2017352033A1 AU 2017352033 A1 AU2017352033 A1 AU 2017352033A1 AU 2017352033 A AU2017352033 A AU 2017352033A AU 2017352033 A AU2017352033 A AU 2017352033A AU 2017352033 A1 AU2017352033 A1 AU 2017352033A1
Authority
AU
Australia
Prior art keywords
acid sequence
amino acid
dose
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017352033A
Other languages
English (en)
Inventor
Fabrizio DE BENEDETTI
Cristina De Min
Walter Ferlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AG
Original Assignee
Swedish Orphan Biovitrum AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum AG filed Critical Swedish Orphan Biovitrum AG
Publication of AU2017352033A1 publication Critical patent/AU2017352033A1/en
Assigned to SWEDISH ORPHAN BIOVITRUM AG reassignment SWEDISH ORPHAN BIOVITRUM AG Request for Assignment Assignors: NOVIMMUNE SA
Priority to AU2024264563A priority Critical patent/AU2024264563A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017352033A 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications Abandoned AU2017352033A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024264563A AU2024264563A1 (en) 2016-10-24 2024-11-12 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411783P 2016-10-24 2016-10-24
US62/411,783 2016-10-24
PCT/IB2017/001427 WO2018078442A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024264563A Division AU2024264563A1 (en) 2016-10-24 2024-11-12 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Publications (1)

Publication Number Publication Date
AU2017352033A1 true AU2017352033A1 (en) 2019-06-06

Family

ID=60957345

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017352033A Abandoned AU2017352033A1 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AU2024264563A Pending AU2024264563A1 (en) 2016-10-24 2024-11-12 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024264563A Pending AU2024264563A1 (en) 2016-10-24 2024-11-12 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Country Status (12)

Country Link
EP (1) EP3528845A2 (OSRAM)
JP (3) JP2019532970A (OSRAM)
KR (2) KR20240148970A (OSRAM)
CN (1) CN110167593A (OSRAM)
AU (2) AU2017352033A1 (OSRAM)
BR (1) BR112019008156A2 (OSRAM)
CA (2) CA3041434A1 (OSRAM)
EA (1) EA201990930A1 (OSRAM)
IL (1) IL266174B2 (OSRAM)
MX (2) MX2019004766A (OSRAM)
SG (1) SG11201903659WA (OSRAM)
WO (1) WO2018078442A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016177913A1 (en) 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
WO2021207150A1 (en) * 2020-04-06 2021-10-14 Celledit Llc Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
MXPA01005515A (es) * 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DK1848744T3 (da) * 2005-01-27 2012-03-19 Novimmune Sa Humane anti-interferon-gamma-antistoffer og fremgangsmåder til anvendelse heraf
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
WO2013078378A1 (en) * 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma
KR20170018810A (ko) 2014-06-10 2017-02-20 메이지 세이카 파루마 가부시키가이샤 안정한 아달리무맙 수성 제제
WO2016177913A1 (en) * 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Also Published As

Publication number Publication date
CA3244670A1 (en) 2025-11-29
KR20240148970A (ko) 2024-10-11
WO2018078442A2 (en) 2018-05-03
JP7562074B2 (ja) 2024-10-07
AU2024264563A1 (en) 2024-11-28
IL266174B2 (en) 2024-10-01
MX2025012950A (es) 2025-12-01
EA201990930A1 (ru) 2019-11-29
CA3041434A1 (en) 2018-05-03
SG11201903659WA (en) 2019-05-30
KR20190071785A (ko) 2019-06-24
JP2024170569A (ja) 2024-12-10
MX2019004766A (es) 2019-09-27
BR112019008156A2 (pt) 2019-07-02
IL266174A (en) 2019-06-30
JP2019532970A (ja) 2019-11-14
WO2018078442A3 (en) 2018-08-23
EP3528845A2 (en) 2019-08-28
JP2022187025A (ja) 2022-12-15
IL266174B1 (en) 2024-06-01
CN110167593A (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
US12275785B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
US12195530B2 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP7562074B2 (ja) インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
Pardeo et al. Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies
Prasad et al. Rheumatoid arthritis: advances in treatment strategies
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
EA049189B1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
Byng-Maddick Differential effects of anti-TNF therapies for inflammatory arthritides on immune responses to Mycobacterium tuberculosis
Lübbers Profiling Seropositive Arthralgia Patients
Lübbers et al. VU Research Portal

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SWEDISH ORPHAN BIOVITRUM AG

Free format text: FORMER APPLICANT(S): NOVIMMUNE SA

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted